Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/80285
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVelumani, Sumathyen
dc.contributor.authorToh, Ying Xiuen
dc.contributor.authorBalasingam, Shobanaen
dc.contributor.authorArchuleta, Sophiaen
dc.contributor.authorLeo, Yee Sinen
dc.contributor.authorGan, Victor C.en
dc.contributor.authorThein, Tun Linnen
dc.contributor.authorWilder-Smith, Anneliesen
dc.contributor.authorFink, Katjaen
dc.date.accessioned2016-04-15T06:21:36Zen
dc.date.accessioned2019-12-06T13:46:27Z-
dc.date.available2016-04-15T06:21:36Zen
dc.date.available2019-12-06T13:46:27Z-
dc.date.issued2016en
dc.identifier.citationVelumani, S., Toh, Y. X., Balasingam, S., Archuleta, S., Leo, Y. S., Gan, V. C., et al. (2016). Low antibody titers five years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees. Human Vaccines & Immunotherapeutics, 12(5), 1265-1273.en
dc.identifier.issn2164-5515en
dc.identifier.urihttps://hdl.handle.net/10356/80285-
dc.description.abstractGlobally, dengue virus (DENV) is one of the most widespread vector-borne viruses. Dengue disease affects populations in endemic areas and, increasingly, tourists who travel to these countries, but there is currently no approved vaccine for dengue. A phase 3 efficacy trial with Sanofi-Pasteur's recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) conducted in South East Asia showed an overall efficacy of 56% against virologically confirmed dengue infections of any severity and any of the four serotypes, but the long-term protection of the vaccine has yet to be demonstrated. To address longevity of antibody titers and B cell memory, we recalled study participants from an earlier CYD immunogenicity study (Phase 2) conducted in Singapore that enrolled healthy volunteers in the year 2009. Depending on the age group, 57–84% of the participants initially generated a neutralizing antibody titer ≥ 10 to all four DENV serotypes 28 days after the third and final dose. We observed very low antibody titers in blood samples collected from 23 vaccinees five years after the first dose, particularly titers of antibodies binding to virus particles compared with those to recombinant E protein. The in vivo efficacy of plasma antibodies against DENV-2 challenge was also tested in a mouse model, which found that only 2 out of 23 samples were able to reduce viremia. Although the sample size is too small for general conclusions, dengue immune memory after vaccination with CYD-TDV appears relatively low.en
dc.format.extent34 p.en
dc.language.isoenen
dc.relation.ispartofseriesHuman Vaccines & Immunotherapeuticsen
dc.rights© 2016 Taylor & Francis Group, LLC. This is the author created version of a work that has been peer reviewed and accepted for publication by Human Vaccines & Immunotherapeutics, Taylor & Francis Group, LLC. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1080/21645515.2015.1126012].en
dc.subjectDengueen
dc.subjectVaccineen
dc.subjectMemory B cellsen
dc.subjectAntibodiesen
dc.subjectImmune memoryen
dc.subjectLong-termen
dc.titleLow antibody titers five years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccineesen
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en
dc.identifier.doi10.1080/21645515.2015.1126012en
dc.description.versionAccepted versionen
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:LKCMedicine Journal Articles

SCOPUSTM   
Citations

16
Updated on Sep 2, 2020

PublonsTM
Citations

14
Updated on Feb 24, 2021

Page view(s)

348
Updated on Mar 1, 2021

Download(s)

91
Updated on Mar 1, 2021

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.